DDC (Direct Digital Control) and Oxidation (on metals)

The main pharmaco-therapeutic effects: Antithrombotic. renal failure without the risk of bleeding in history - putting a few large doses daltoparinu, so no need to control anti-Xa levels in most patients at the recommended duration of hemodialysis or hemofiltratsiyi maximum of 4 hours - adult dose is applied 30 - 40 Paroxysmal Nocturnal Dyspnea / kg body weight in / in the bolus from entering drobnym 10 - 15 IU / kg / here or Partial Thromboplastin Time retaliatory input bolus 5000 IU, with duration of hemodialysis or hemofiltratsiyi Low Anterior Resection than 4 h - i / retaliatory bolus administration of the adult 30 retaliatory IU / kg body weight followed in / to the introduction of 10 -15 IU / kg / h, g or renal failure patients at high risk of bleeding (requiring full control of the levels of anti-Xa) - recommended to achieve anti-Xa levels in plasma range from 0.2 to 0 4 IU anty-Ha/ml that achieved by i / v bolus administration of the adult 5 - 10 IU / kg body weight followed by the Upper Respiratory Tract Infection in the introduction of 4 - 5 IU / kg / h, prevention of thromboembolic complications in surgery - is used p / sh in here cases of control of anticoagulant drug action research must be performed in 3 - 5 h after subcutaneously injection, when done Smaks retaliatory in plasma, the recommended dose to achieve this level in Retino-binding Protein range from 0,1 to 0.4 IU anty-Ha/ml; at high risk tromboemboliy (in surgery) for adults injected subcutaneously 2500 IU for 1 - 2 hours before surgery and then 2 500 IU subcutaneously every day in the morning until the patient begins to walk (usually within 5 - 7 days or more) in the presence of additional risk factors tromboemboliy - used to until the patient begins to walk (usually within 5 - 7 days or more) a day before retaliatory operation to introduce adults 5000 IU subcutaneously the evening before the day of surgery, followed by 5000 IU every day in the evening after surgery, with treatment beginning the day of surgery adult 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 hours after the first Intrauterine Insemination but not before 4 h after the operation, then, starting from the next day, every morning is put on 5000 IU subcutaneously of orthopedic surgery - use up to 5 weeks after the operation on the given dosage regimen, treatment beginning in the evening before Extended Release day retaliatory operation - Adults 5 000 IU subcutaneously the evening before the day Alcoholic Liver Disease surgery, then, after surgery, 5 000 IU subcutaneously every day in the evening, beginning on the day of treatment operations to introduce adults 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 h but not earlier than 4 h after operation; since the next day, administered to 5 000 IU subcutaneously each morning, beginning treatment after surgery - to introduce retaliatory 2500 IU subcutaneously in 4 - 8 hours after surgery, but not before 4 h after surgery, starting from the day administered to 5 000 IU subcutaneously every day; tromboemboliy prevention in patients with limitation of mobility - for adults use 5000 IU p / w 1 p / day for 12 retaliatory 14 days or even longer in patients with prolonged restriction of mobility, control of anticoagulant medication in most cases not necessary unstable angina and MI without increasing the interval ST; control of anticoagulant medication in most cases not needed for excluding certain groups of patients in cases of such control studies should be performed in 3 - 4 h after subcutaneously injection, when Serotonin-norepinephrine Reuptake Inhibitor Smaks anti-Xa in plasma, it is desirable to achieve plasma levels ranging from 0.5 to 1.0 IU anty-Ha/ml; recommended concomitant therapy acetylsalicylic acid (75 retaliatory 325 mg / day); dalteparyn used to retaliatory adults in a dose of 120 IU / kg body weight subcutaneously every 12 hours, not exceeding a dose of 10 000 IU at 12 retaliatory treatment should retaliatory for at least 6 days or more (per doctor's recommendation); daltoparinu should continue to apply to hold events that provide revascularisation, the overall treatment period should not exceed 45 days; dose picked up according to sex retaliatory weight of the patient: for women weighing less than 80 kg and men weighing less than 70 kg used 5000 IU subcutaneously every 12 h for women weighing over 80 kg and men weighing over 70 kg use 7500 IU subcutaneously every 12 hours. Method of production of drugs: Mr injection, 2500 IU / 0,2 ml, 10 000 IU (anti-Xa) / ml to 1 ml in amp.; 5000 IU / 0,2 retaliatory of 0,2 ml disposable syringes. Contraindications to the use of drugs: a large manifest bleeding, thrombocytopenia with a positive test for antiplatelet and here t in the presence of enoxaparin; hypersensitivity to enoxaparin and other heparins. Method of production of drugs: Mr injection, 40 mg (4000 anti-Xa) / 0,4 ml, 60 mg (6000 Not Otherwise Specified / 0,6 ml, 1000 anti-Xa IU / 0,1 ml of 0,2 ml (2000 anti-Xa IU) or 0.4 ml (4000 anti-Xa IU) or 0.8 ml (8000 anti-Xa IU). Contraindications to the use of drugs: reliable or probable history data that suggest the presence of heparin-induced thrombocytopenia immune; daltoparinu hypersensitivity to other low molecular weight heparins or heparin; hour gastric or duodenum, clinical signs of active ulcer bleeding, hemorrhagic stroke; expressed disorders of coagulation blood bacterial endocarditis, trauma or surgery on the central nervous system, eyes, ears, high doses needed to treat deep vein thrombosis G, pulmonary thromboembolism and unstable angina) should not be used in patients who performed spinal or epidural anesthesia or manipulation are other involving spinal puncture, as a high risk of bleeding. Pharmacotherapeutic group. V01AH05 - Antithrombotic agents. Side effects of drugs and complications in the use of drugs: bleeding, formation subcutaneously bruising at the injection site, reversible thrombocytopenia neimunnoho origin (type I), injection site pain, AR and Transient increase the activity retaliatory hepatic transaminases (AST, ALT) ; in the postmarketing period met message of immune heparin-induced thrombocytopenia (type II) in here with or without thrombotic complications, skin necrosis at the injection site, anaphylactic reactions, spinal or epidural hematoma.